Assessment cycle 2023 Q4
Documents ratified in the 2023 Q4 assessment cycle, which ran from 1 October 2023 to 31 December 2023 and was ratified on 22 December 2023.
Documents ratified
-
Record of documents ratified in the 2023 Q4 assessment cycle.
22 Dec 2023 -
Consultation on the draft standard specifying the minimum data a certificate of analysis must carry before the Institute will treat it as interpretable. The draft…
12 Dec 2023 -
Consultation on the scope and drafting conventions of the analytical and methodological standards series. The central question put was whether an Institute standard…
28 Dec 2023 -
Recurrent upper-airway obstruction during sleep producing apnoeas and hypopnoeas, graded by the apnoea–hypopnoea index on polysomnography.
09 Oct 2023 -
Long-acting amylin and calcitonin receptor agonist (acylated). Amylin is co-secreted with insulin and acts at the area postrema to promote meal-related satiation, and separately reduces gastric emptying and…
Moderate06 Feb 2025 -
GLP-1 receptor agonist (acylated, once-daily). Receptor pharmacology is that of the selective GLP-1 class. The pharmacokinetic engineering differs: self-association into heptamers at the…
High27 Aug 2024 -
Unimolecular amylin and GLP-1 receptor co-agonist. A single peptide engineered to activate both the amylin and GLP-1 receptor systems, combining two complementary satiation mechanisms without the…
Low11 Aug 2024 -
Growth-hormone-releasing hormone analogue. Tesamorelin stimulates the pituitary to release endogenous growth hormone in a pulsatile pattern, preserving the physiological feedback architecture…
Moderate01 Sep 2024 -
Growth-hormone secretagogue, ghrelin receptor agonist (hexapeptide). Ghrelin receptor agonism producing growth-hormone release. Its approved use is a single-dose provocative diagnostic test, for which the acute…
Low17 Apr 2024